Skip to content

Study · Randomized controlled trial · n = 120 · 1996

2 results

Salmon calcitonin in the prevention of bone loss at perimenopause.

Arnala I, Saastamoinen J, Alhava EM

Bone1 Jun 1996Cited by 22 (Europe PMC)

PMID8806006 (opens in a new tab)DOI10.1016/8756-3282(96)00084-1 (opens in a new tab)PepBankPUB-08806006
Publisher pagePubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

2 results from studies that gave the peptide. 2 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In perimenopausal women, biochemical parameters did not differ between calcitonin and placebo groups.

    In plain wordsIn perimenopausal women, blood chemistry results did not differ between calcitonin and placebo.

    Peptide
    Calcitonin-salmon
    Outcome
    No significant changeBiochemical parameters
    Study

    n = 120

    Comparator
    placebo
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    100 IU daily · intranasalAs given in this study (human).

    Source sentences

    Summary
    There was no difference in biochemical parameters between the groups.
    3 context sentences
    Summary · context
    A double-blind study of 120 perimenopausal women without present or past disease or medication that could affect bone metabolism were studied.
    Summary · context
    The subjects were randomized in two groups and provided with nasal spray bottles containing either placebo (excipient only) or active compound (excipient plus 50 international units (IU) salmon calcitonin per dose).
    Summary · context
    All subjects took one soluble tablet of calcium (1000 mg) per day.
  2. 02HumanNon-randomized trialEfficacy outcome

    In perimenopausal women receiving calcitonin or placebo, no fractures occurred during the study.

    In plain wordsNo fractures occurred in perimenopausal women receiving calcitonin or placebo.

    Peptide
    Calcitonin-salmon
    Outcome
    Not applicableFractures
    Study

    n = 120

    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    100 IU daily · intranasalAs given in this study (human).

    Source sentences

    Summary
    No fractures were recorded during the study period.
    3 context sentences
    Summary · context
    A double-blind study of 120 perimenopausal women without present or past disease or medication that could affect bone metabolism were studied.
    Summary · context
    The subjects were randomized in two groups and provided with nasal spray bottles containing either placebo (excipient only) or active compound (excipient plus 50 international units (IU) salmon calcitonin per dose).
    Summary · context
    All subjects took one soluble tablet of calcium (1000 mg) per day.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:35 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.